Health Innovation
5 Spanish Health Startups Emerging Across Diagnostics and Biotech
DealBio tracks early-stage health startups across Europe and North America. These 5 Spanish startups show a clear pattern: health products built around complex biological signals that need interpretation before they can change care.
- Spain
- Diagnostics
- Biotech
- Clinical AI
- Microbiome
DealBio tracks early-stage health startups across Europe and North America. These 5 Spanish startups show a clear pattern: health products built around complex biological signals that need interpretation before they can change care.
The strongest theme is not diagnostics alone, or biotech alone. It is the layer between raw biology and a useful decision. Biotasmart and AIMA Biotech turn microbiome data into professional-facing reports. BASE4 Biosciences applies molecular models to ageing and reproductive health. Bioinspired Intelligence turns glucose patterns into forecasts for insulin decisions.
Synflora adds a more therapeutic angle, using engineered skin bacteria as the delivery system rather than as a diagnostic input. That makes the group broader, but the investor question stays consistent: can the startup turn a difficult biological system into a product that clinicians, patients or care teams can use repeatedly?
At a Glance
- SynfloraSpain2026Engineered skin bacteria for dermatology
- BiotasmartSpain2024Gut and vaginal microbiome reports
- BASE4 BiosciencesSpain2025Blood-based biological-age and reproductive-health models
- Bioinspired IntelligenceSpain2025Glucose forecasts for insulin decisions
- AIMA BiotechSpain2026Clinician-guided microbiome testing
01
Synflora
Engineering skin bacteria to deliver therapies inside hair follicles.
- Country
Spain- Founded
- 2026
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why Synflora stands out
Synflora’s founding science connects microbial engineering with a specific skin-delivery problem. A 2024 Nature Biotechnology study demonstrated engineered skin bacteria producing and secreting a skin-oil-regulating protein in mice.
The EU awarded €2.5 million to the UPF-coordinated SkinEngineering project to advance the platform, including manufacturing and safety development.
What Synflora is building
Synflora modifies Cutibacterium acnes, a bacterium that naturally lives in hair follicles, to produce selected therapeutic molecules.
Its early acne programme focuses on sebum and inflammation, with a preclinical platform designed for sustained local delivery near the target tissue.
Interprets gut and vaginal microbiome tests for personalized nutritional guidance.
- Country
- Spain
- Founded
- 2024
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
- Founders
Why Biotasmart stands out
Biotasmart announced €500,000 in financing in February 2026, led by Angels with Dacsa Group and individual investors.
The startup exceeded 50 users in its first commercial year and sells microbiome interpretation through health and nutrition professionals rather than leaving patients to interpret sequencing reports alone.
What Biotasmart is building
Biotasmart coordinates sample collection, sequencing by a specialist laboratory and in-house interpretation for gut and vaginal microbiome tests.
Reports are non-diagnostic and are designed for discussion with professionals, including in women’s health, fertility, menopause and nutrition consultations.
Developing blood tests for organ aging and women’s reproductive health.
- Country
- Spain
- Founded
- 2025
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
Why BASE4 Biosciences stands out
BASE4 Biosciences raised $1 million in pre-seed financing in April 2026, backed by Baobab Ventures, Kfund, Itnig, Masia and angel investors.
A technology-transfer agreement with Sant Pau transferred the underlying patent to the startup, connecting the commercial product to institutional research.
What BASE4 Biosciences is building
BASE4 Biosciences is developing blood tests that measure gene activity and other molecular signals. AI models tailored by sex estimate the biological state of different tissues.
The first focus areas include ovarian ageing and reproductive health, with insights intended for discussion with qualified health professionals.
Developing AI software to forecast glucose and support insulin-dosing decisions.
- Country
- Spain
- Founded
- 2025
- Sector
- Digital health
- Funding stage
- Seed or earlier
Why Bioinspired Intelligence stands out
Bioinspired Intelligence’s glUCModel entered a randomized clinical evaluation in July 2025 involving adults with type 1 diabetes using insulin injections.
All three founders are named on a published glucose-prediction patent application assigned to Complutense and Extremadura universities.
What Bioinspired Intelligence is building
glUCModel combines personalised glucose forecasts, configurable warnings and insulin-dose recommendations in a mobile app.
The system forecasts changes up to two hours ahead and is being evaluated alongside usual insulin-injection routines.
Offering clinician-guided gut microbiome testing with AI-assisted interpretation.
- Country
- Spain
- Founded
- 2026
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
Why AIMA Biotech stands out
AIMA Biotech’s live platform states that more than 100 healthcare professionals use its service across nutrition, medical practice, sports centres and longevity clinics.
Its co-founders bring prior experience at microbiome sequencing provider Microomics, genomics company Binartis and data-technology roles.
What AIMA Biotech is building
AIMA offers gut microbiota tests through healthcare professionals. A home-collected stool sample is analysed in a laboratory, then sequencing results and questionnaires feed a clinician-reviewed platform.
AIMA Care generates AI-assisted interpretation that the professional reviews, edits and contextualizes before producing a report under the clinic’s own branding.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
The investment signal in this Spanish group is the move from biological complexity to usable interpretation. Sequencing, gene expression and glucose data do not create value simply because they are rich datasets. They create value when they shape a clinical recommendation, a professional consultation, a treatment decision or a repeatable consumer-health workflow.
For investors, that makes workflow ownership important. The question is who controls the interpretation step, who is trusted to act on the result, and whether the startup can build a defensible service layer around data that might otherwise be commoditized by laboratories, software vendors or larger care platforms.
Methodology
DealBio selected these startups from its database of early-stage health and longevity startups, focusing on Spain-based businesses with published DealBio Startup Briefs and clear activity across diagnostics, biotechnology, microbiome science or clinical AI. The selection favours startups with specific product workflows and avoids padding with unrelated Spanish health businesses. DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.